These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8686186)
1. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease]. Lukás K Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186 [No Abstract] [Full Text] [Related]
2. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid]. Frol'kis AV Ter Arkh; 1996; 68(2):75-7. PubMed ID: 8771669 [No Abstract] [Full Text] [Related]
3. [5-ASA versus sulfasalazine]. Varela E Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405 [No Abstract] [Full Text] [Related]
4. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Ryan BM; Russel MG; Langholz E; Stockbrugger RW Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319 [TBL] [Abstract][Full Text] [Related]
5. [Changing treatment of inflammatory bowel diseases]. Karvonen AL; Matikainen M; Turunen U Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809 [No Abstract] [Full Text] [Related]
6. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
7. 5-aminosalicylates in inflammatory bowel disease--the more the merrier? Forbes A Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1017-9. PubMed ID: 8680898 [No Abstract] [Full Text] [Related]
8. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?]. Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975 [TBL] [Abstract][Full Text] [Related]
12. Safety of balsalazide therapy in the treatment of inflammatory bowel disease. Baker DE Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348 [TBL] [Abstract][Full Text] [Related]
13. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases. Liu ZC; McClelland RA; Uetrecht JP Drug Metab Dispos; 1995 Feb; 23(2):246-50. PubMed ID: 7736919 [TBL] [Abstract][Full Text] [Related]
15. Conventional drug therapy in inflammatory bowel disease. Griffin MG; Miner PB Gastroenterol Clin North Am; 1995 Sep; 24(3):509-21. PubMed ID: 8809233 [TBL] [Abstract][Full Text] [Related]
16. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Riley SA; Turnberg LA Q J Med; 1990 Jun; 75(278):551-62. PubMed ID: 1977185 [No Abstract] [Full Text] [Related]
17. Management of inflammatory bowel disease. Proceedings of an international symposium on mesalazine. frankfurt, 23-25 March 1988. Scand J Gastroenterol Suppl; 1990; 172():1-68. PubMed ID: 2353167 [No Abstract] [Full Text] [Related]
18. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Kreisel W; Wolf LM; Grotz W; Grieshaber M Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875 [TBL] [Abstract][Full Text] [Related]
19. Medical treatment of inflammatory bowel disease. Singhal A; Kar P J Assoc Physicians India; 1995 Sep; 43(9):627-31. PubMed ID: 8773067 [No Abstract] [Full Text] [Related]
20. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A; Rankin GB; Seidner DL; Lashner BA Cleve Clin J Med; 1995; 62(5):317-23. PubMed ID: 7586488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]